Stay updated on ONC-392 & Pembrolizumab in Platinum Resistant Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the ONC-392 & Pembrolizumab in Platinum Resistant Ovarian Cancer Clinical Trial page.

Latest updates to the ONC-392 & Pembrolizumab in Platinum Resistant Ovarian Cancer Clinical Trial page
- Check2 days agoChange DetectedThe page’s revision/version indicator was updated from v3.5.2 to v3.5.3. This represents a site release/version change rather than a modification to the clinical trial record content.SummaryDifference0.1%

- Check9 days agoChange DetectedAdded a 2026-04-13 entry for Study Status and updated to Revision: v3.5.2, with an accompanying 2026-04-08 entry; removed Revision: v3.5.0.SummaryDifference0.5%

- Check17 days agoChange DetectedRemoved the References and Oversight sections from the study record history view.SummaryDifference0.2%

- Check38 days agoChange DetectedAdded revision 3.5.0 to the history and removed revision 3.4.3.SummaryDifference0.1%

- Check53 days agoChange DetectedAdded revision v3.4.3 to the record history and removed the previous v3.4.2 entry.SummaryDifference0.1%

- Check74 days agoChange DetectedThe page shows a minor site version update: Revision v3.4.2 added and Revision v3.4.1 removed. This change does not affect the study data or history content displayed on the page.SummaryDifference0.1%

Stay in the know with updates to ONC-392 & Pembrolizumab in Platinum Resistant Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ONC-392 & Pembrolizumab in Platinum Resistant Ovarian Cancer Clinical Trial page.